Radafaxine

Radafaxine
Clinical data
ATC code none
Identifiers
CAS Number 106083-71-0 N
PubChem (CID) 9795056
ChemSpider 7970823 YesY
UNII Q47741214K YesY
ChEMBL CHEMBL1172928 YesY
Chemical and physical data
Formula C13H18ClNO2
Molar mass 292.20 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Radafaxine is drug candidate designated GW-353,162[1] by GlaxoSmithKline, investigated for treatment of restless leg syndrome and as an NDRI antidepressant. GlaxoSmithKline was targeting Radafaxine for regulatory filing in 2007,[2] but development was discontinued in 2006 due to "poor test results".[3]

Chemistry

It is a potent metabolite of bupropion, the compound in GlaxoSmithKline's Wellbutrin. More specifically, "hydroxybupropion" is an analogue of bupropion, and radafaxine is an isolated isomer ((2S,3S)-) of hydroxybupropion.[4]

Therefore, radafaxine builds on at least some of the properties of bupropion in humans.[5]

Effects

In various clinical trials, radafaxine has been studied as a treatment for clinical depression, obesity, and neuropathic pain. Radafaxine is described as a norepinephrine-dopamine reuptake inhibitor (NDRI).

Unlike bupropion (which has a much higher effect on dopamine reuptake), radafaxine seems to have a higher potency on norepinephrine. Radafaxine has about 70% of bupropion's efficacy in blocking dopamine reuptake, and 392% of efficacy in blocking norepinephrine reuptake, making it fairly selective for inhibiting the reuptake of norepinephrine over dopamine.[6][7] This, according to GlaxoSmithKline, may account for the increased effect of radafaxine on pain and fatigue.[8]

At least one study suggests that radafaxine has a low abuse potential similar to bupropion.[9]

See also

References

  1. Restless Legs Syndrome: First Approval
  2. {1} Reviews Novel Therapeutics For CNS Disorders And Confirms Strong Pipeline Momentum - News, Search Jobs, Events
  3. Independent.co.uk: GSK breakthrough on bird flu vaccine.
  4. radafaxine at the US National Library of Medicine Medical Subject Headings (MeSH)
  5. GlaxoSmithKline Reviews Novel Therapeutics for CNS Disorders and Confirms Strong Pipeline Momentum
  6. Xu H, Loboz KK, Gross AS, McLachlan AJ (2007). "Stereoselective analysis of hydroxybupropion and application to drug interaction studies". Chirality. 19 (3): 163–70. doi:10.1002/chir.20356. PMID 17167747.
  7. Bondarev ML, Bondareva TS, Young R, Glennon RA (2003). "Behavioral and biochemical investigations of bupropion metabolites". Eur J Pharmacol. 474 (1): 85–93. doi:10.1016/S0014-2999(03)02010-7. PMID 12909199.
  8. Microsoft PowerPoint - slides_05_burch.ppt
  9. Radafaxine
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.